This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shortt J, Spencer A . Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38: 433–436.
Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486–1488.
Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR . High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone Marrow Transplant 2004; 33: 1011–1014.
Asmar BI, Andresen J, Brown WJ . Ureaplasma urealyticum arthritis and bacteremia in agammaglobulinemia. Pediatr Infect Dis J 1998; 17: 73–76.
Held G, Poschel V, Pfreundschuh M . Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006; 6: 1175–1186.
Van Besien K . The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006; 20: 235–244.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783.
Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C . Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62: 43–52.
Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 2007; 137: 349–354.
Acknowledgements
This work was supported by a grant of the Regional Cancer League Basel-Stadt (CA) and a grant of the Swiss National Research Foundation 3200B0-106105/1 (AG). We thank the stem cell transplantation team and the intensive care unit team for devoted patient care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arber, C., Buser, A., Heim, D. et al. Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment. Bone Marrow Transplant 40, 597–598 (2007). https://doi.org/10.1038/sj.bmt.1705766
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705766
This article is cited by
-
Metagenomic next-generation sequencing restores the diagnosis of a rare infectious complication of B cell depletion
European Journal of Clinical Microbiology & Infectious Diseases (2022)
-
Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT
Bone Marrow Transplantation (2009)
-
Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Bone Marrow Transplantation (2008)